Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease

Background: Alzheimer's disease (AD), the commonest form of dementia, affects people in both industrialised and developing countries. Risk factors for the development of AD include age, the presence of the Apolipoprotein ε4 allele, low vitamin B₁₂ and folate levels, and elevated plasma homocysteine...

Full description

Saved in:
Bibliographic Details
Main Author: Mohamed, Ilhaam
Other Authors: Combrinck, M I
Format: Thesis
Language:English
Published: Division of Geriatric Medicine 2017
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613239513186304
access_status_str Open Access
author Mohamed, Ilhaam
author2 Combrinck, M I
author_browse Combrinck, M I
Mohamed, Ilhaam
author_facet Combrinck, M I
Mohamed, Ilhaam
author_sort Mohamed, Ilhaam
collection Thesis
description Background: Alzheimer's disease (AD), the commonest form of dementia, affects people in both industrialised and developing countries. Risk factors for the development of AD include age, the presence of the Apolipoprotein ε4 allele, low vitamin B₁₂ and folate levels, and elevated plasma homocysteine concentrations. Most research involving the associations between these risk factors and AD have been conducted in Europe and North America. We know little about AD and its risk factors in a low to middle income country like South Africa, where nutrition is poor and the background population ApoE ε4 allelic frequency is high. Objective: In this prospective observational study, I wished to determine the relationships between plasma homocysteine, vitamin B₁₂, folate, ApoE ε4 status and cognition in a sample of older persons from the greater Cape Town metropolitan area of the Western Cape region of South Africa. Methods: Cognitively healthy controls and AD participants, diagnosed using NINCDS-ADRDA criteria, were recruited from the community. The study had both cross-sectional and longitudinal components. Cross-sectionally, I related non-fasting plasma homocysteine concentrations, vitamin B₁₂ levels, folate concentrations and the ApoE ε4 genotype to scores from a battery of cognitive tests including the Mini Mental State Examination (MMSE), the Cambridge Cognitive Examination (CAMCOG) and the Learning Subscale score of the CAMCOG. In the longitudinal analysis, I tested whether baseline plasma homocysteine concentrations related to cognitive decline one year after the initial assessment. Results: One hundred and thirteen participants were recruited: 60 controls and 53 AD participants. Plasma homocysteine levels increased with age (rs= 0.418, p<0.001) and were inversely related to cognitive scores in all participants. Homocysteine concentrations were inversely related to vitamin B₁₂ and folate in all study participants (vitamin B₁₂rₛ= -0.47, p<0.001, folaterₛ=-0.33, p=0.001). Homocysteine was inversely related to cognition but, in a regression model, this relation was confounded by the effects of age and years of education. Another regression model showed that vitamin B₁₂ and age independently predicted cognitive scores. There were more ApoE ε4 carriers in the AD group compared with controls and ε4 carrier status was significantly associated with AD. The ApoE ε4 allele modified the relationship between homocysteine and cognition. The association between homocysteine and cognition was strong in ApoE ε4 carriers (e.g. MMSE,rₛ=0.33, p=0.003), but absent in ε4 non-carriers. High baseline homocysteine concentrations did not predict cognitive decline 1 year later. Conclusions: These findings, the first from an African low to middle income country, are consistent with those from studies in industrialised countries. Plasma homocysteine levels increased with age and were inversely related to vitamin B₁₂ and folate. The ApoE ε4 allele strengthened the association between homocysteine and cognition, probably through mechanisms that increase neuronal susceptibility to homocysteine toxicity. My study supports the idea that homocysteine-lowering therapy can reduce the risk of developing AD or slow the progression of the disease.
format Thesis
id oai:open.uct.ac.za:11427/23064
institution University of Cape Town (South Africa)
language eng
last_indexed 2026-06-10T12:32:58.612Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository
publishDate 2017
publishDateRange 2017
publishDateSort 2017
publisher Division of Geriatric Medicine
publisherStr Division of Geriatric Medicine
record_format dspace
source_str UCTD — University of Cape Town Open Access Repository
spelling oai:open.uct.ac.za:11427/23064 The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease Mohamed, Ilhaam Combrinck, M I Geriatric Medicine Background: Alzheimer's disease (AD), the commonest form of dementia, affects people in both industrialised and developing countries. Risk factors for the development of AD include age, the presence of the Apolipoprotein ε4 allele, low vitamin B₁₂ and folate levels, and elevated plasma homocysteine concentrations. Most research involving the associations between these risk factors and AD have been conducted in Europe and North America. We know little about AD and its risk factors in a low to middle income country like South Africa, where nutrition is poor and the background population ApoE ε4 allelic frequency is high. Objective: In this prospective observational study, I wished to determine the relationships between plasma homocysteine, vitamin B₁₂, folate, ApoE ε4 status and cognition in a sample of older persons from the greater Cape Town metropolitan area of the Western Cape region of South Africa. Methods: Cognitively healthy controls and AD participants, diagnosed using NINCDS-ADRDA criteria, were recruited from the community. The study had both cross-sectional and longitudinal components. Cross-sectionally, I related non-fasting plasma homocysteine concentrations, vitamin B₁₂ levels, folate concentrations and the ApoE ε4 genotype to scores from a battery of cognitive tests including the Mini Mental State Examination (MMSE), the Cambridge Cognitive Examination (CAMCOG) and the Learning Subscale score of the CAMCOG. In the longitudinal analysis, I tested whether baseline plasma homocysteine concentrations related to cognitive decline one year after the initial assessment. Results: One hundred and thirteen participants were recruited: 60 controls and 53 AD participants. Plasma homocysteine levels increased with age (rs= 0.418, p<0.001) and were inversely related to cognitive scores in all participants. Homocysteine concentrations were inversely related to vitamin B₁₂ and folate in all study participants (vitamin B₁₂rₛ= -0.47, p<0.001, folaterₛ=-0.33, p=0.001). Homocysteine was inversely related to cognition but, in a regression model, this relation was confounded by the effects of age and years of education. Another regression model showed that vitamin B₁₂ and age independently predicted cognitive scores. There were more ApoE ε4 carriers in the AD group compared with controls and ε4 carrier status was significantly associated with AD. The ApoE ε4 allele modified the relationship between homocysteine and cognition. The association between homocysteine and cognition was strong in ApoE ε4 carriers (e.g. MMSE,rₛ=0.33, p=0.003), but absent in ε4 non-carriers. High baseline homocysteine concentrations did not predict cognitive decline 1 year later. Conclusions: These findings, the first from an African low to middle income country, are consistent with those from studies in industrialised countries. Plasma homocysteine levels increased with age and were inversely related to vitamin B₁₂ and folate. The ApoE ε4 allele strengthened the association between homocysteine and cognition, probably through mechanisms that increase neuronal susceptibility to homocysteine toxicity. My study supports the idea that homocysteine-lowering therapy can reduce the risk of developing AD or slow the progression of the disease. 2017-01-25T14:12:58Z 2017-01-25T14:12:58Z 2014 2016-12-12T14:07:18Z Master Thesis Masters MMed http://hdl.handle.net/11427/23064 eng application/pdf Division of Geriatric Medicine Faculty of Health Sciences University of Cape Town
spellingShingle Geriatric Medicine
Mohamed, Ilhaam
The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease
thesis_degree_str Master's
title The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease
title_full The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease
title_fullStr The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease
title_full_unstemmed The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease
title_short The associations between plasma homocysteine, vitamin B12, folate, the Apolipoprotein E genotype and Alzheimer's Disease
title_sort associations between plasma homocysteine vitamin b12 folate the apolipoprotein e genotype and alzheimer s disease
topic Geriatric Medicine
url http://hdl.handle.net/11427/23064
work_keys_str_mv AT mohamedilhaam theassociationsbetweenplasmahomocysteinevitaminb12folatetheapolipoproteinegenotypeandalzheimersdisease
AT mohamedilhaam associationsbetweenplasmahomocysteinevitaminb12folatetheapolipoproteinegenotypeandalzheimersdisease